🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Accuray Incorporated ARAY R2K

Healthcare · Medical Devices · United States
https://www.accuray.com

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

READ MORE ›
$0.38
-75.16% 1Y

Market & Price

Market Cap
$45.02M
Current Price
$0.38
High / Low (52W)
$1.85 / $0.27
Beta
1.43

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
29.49
Book Value
$0.35
Price to Book
1.08
P/S
0.11
EV/EBITDA
-33.86
Dividend Yield
-

Profitability & Returns

ROCE
5.07%
ROE
-101.06%
ROA
-1.65%
Profit Margin
-10.76%
Op Margin
-2.43%
EPS (Latest Qtr)
$-0.09
EPS (TTM)
$-0.38

Balance Sheet & Liquidity

Debt/Equity
4.37
Quick Ratio
0.58
Current Ratio
1.42
Debt
$182.40M
Total Assets
$470.24M
Current Assets
$317.46M
Working Capital
$124.89M

Ownership

Promoter Holding
4.09%
Chg in Prom Hold
-0.01%
FII / Inst Holding
69.15%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
$189.35M
Total Revenue (TTM)
$428.57M
EBITDA
$-5.59M
Free Cash Flow
$-10.88M
Operating Cash Flow
$-19.12M
Shares Outstanding
118.96M
Gross Margin
26.92%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
2.17%
Profit 5Y
23.41%
Revenue (YoY)
-7.40%
Earnings (YoY)
-

PROS

  • Profit CAGR of 23.4% over 5 years.

CONS

  • Trading 79.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ARAY Accuray Incorporated R2K 0.38 - $45.02M - 5.07% -101.06% 2.17% 23.41%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Sep 2022Dec 2022Mar 2023Sep 2023Dec 2023Mar 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --------90.95M100.33M99.83M113.79M95.83M102.32M103.22M117.42M89.58M98.83M99.55M94.98M85.33M97.46M102.56M110.94M107.44M116.28M96.17M96.49M114.76M118.06M103.89M107.24M101.13M101.55M-113.24M127.54M93.94M102.24M104.84M
Cost of Revenue -----------------------------------81.62M88.56M67.39M78.17M79.55M
Gross Profit 33.90M42.57M44.94M37.30M31.34M31.39M35.42M43.19M38.11M39.35M36.25M47.98M37.88M38.38M40.47M45.93M32.94M37.90M39.13M39.74M35.40M40.83M39.54M43.73M39.52M42.63M34.78M34.60M42.97M38.72M39.49M35.90M29.07M34.47M-31.63M38.98M26.55M24.07M25.29M
Operating Expenses -----------------------------------30.58M34.74M37.86M29.56M27.84M
Operating Income -7.23M-124.00K5.44M--6.55M-4.82M-1.27M--2.05M-1.02M-3.82M--4.69M-868.00K2.88M--4.28M3.62M7.97M-5.47M8.20M4.43M-2.41M3.98M-292.00K-2.18M2.71M2.32M2.21M-3.96M-4.56M-2.15M-1.05M4.23M-11.31M-5.49M-2.55M
EBITDA -----------------------------------3.62M7.89M-11.48M-3.33M-813.00K
Interest Expense -----------------------------------2.89M4.23M8.05M7.71M8.45M
Pretax Income ------------------------------------840.00K2.07M-21.21M-13.20M-11.34M
Tax Provision ----------------------------------695.00K457.00K948.00K471.00K-468.00K
Net Income -13.03M-6.03M756.00K-7.21M-9.93M-9.37M-5.03M-5.25M-9.38M-4.72M-8.85M-946.00K-9.21M-4.64M-1.18M-1.40M-9.36M10.71M2.62M-152.00K402.00K4.77M-390.00K-11.09M-1.03M179.00K-1.05M-5.45M-1.87M599.00K-2.97M-9.62M-6.34M-3.95M--1.30M1.12M-21.68M-13.77M-11.80M
Diluted EPS -0.16-0.080.01-0.09---0.06-------0.05-0.01--0.110.120.030.000.000.050.00-0.12-0.010.00-0.01-0.06-0.020.01-0.03-0.10-0.06-0.04--0.010.01-0.18-0.11-0.09
R&D Expense 14.30M14.93M13.27M-12.23M11.94M12.48M-14.09M14.66M13.91M-13.89M13.64M12.91M-13.34M13.06M11.16M-12.15M11.96M13.27M-14.38M14.70M14.10M14.09M14.64M14.21M14.01M15.28M10.91M12.12M13.64M10.71M-11.37M10.65M8.18M

Profit & Loss (Annual)

Figures in USD.

Metric Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Revenue ------398.80M383.41M404.90M418.79M382.93M-429.91M447.61M446.55M458.50M
Cost of Revenue ------------269.95M293.64M303.63M311.54M
Gross Profit 104.02M107.24M137.27M97.64M142.80M145.40M158.71M141.34M161.69M162.65M149.72M-159.96M153.96M142.92M146.97M
Operating Expenses ------------151.81M151.58M142.42M139.13M
Operating Income 2.84M-27.83M-56.23M-80.66M-18.14M-19.17M-4.87M-9.82M-3.80M583.00K12.54M-8.15M2.38M504.00K7.84M
EBITDA ------------11.64M8.37M5.71M20.24M
Interest Expense ------------8.13M10.63M11.62M12.95M
Pretax Income -------------2.00M-6.79M-11.82M1.13M
Tax Provision ------------3.35M2.49M3.73M2.73M
Net Income -----35.45M-40.21M-25.50M-29.58M-23.90M-16.43M3.83M--5.35M-9.28M-15.54M-1.59M
Diluted EPS 0.05-0.44-1.02------0.28-0.190.04--0.06-0.10-0.16-0.02
R&D Expense 31.52M41.30M81.29M66.20M53.72M55.75M56.65M49.92M57.25M56.49M49.78M52.73M57.75M57.13M49.73M47.94M

Compounded Sales Growth

5 Years:2.17%
1 Year:-7.40%

Compounded Profit Growth

5 Years:23.41%
1 Year:-

Stock Price Performance

1 Year:-75.16%
6 Months:-62.38%
3 Months:-34.48%
1 Month:-9.52%

Balance Sheet (Annual)

Figures in USD.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Total Assets --455.78M473.17M475.93M495.19M466.77M469.03M406.46M378.73M438.18M490.93M-472.85M479.21M468.63M470.24M
Current Assets -------------350.89M338.03M323.24M317.46M
Cash & Equivalents 36.84M45.43M95.91M143.50M73.31M92.35M79.55M119.77M72.08M83.08M76.80M107.58M-88.74M89.40M68.57M57.42M
Inventory -------------142.25M145.15M138.32M141.02M
Receivables -------------94.44M74.78M92.00M83.19M
Total Liabilities --215.46M269.30M369.09M396.64M390.99M409.37M359.93M330.10M388.31M427.29M-419.66M425.56M423.54M389.07M
Current Liabilities --203.04M174.17M155.86M184.57M169.91M210.21M284.49M169.43M192.18M182.27M-208.86M198.64M195.27M192.58M
Long Term Debt ------199.66M170.51M51.55M131.08M159.84M189.31M-171.91M171.56M164.40M123.79M
Total Debt -------------199.49M205.04M210.75M176.38M
Total Equity --240.33M203.87M106.83M98.55M75.78M59.66M46.53M48.63M49.87M63.63M-53.19M53.66M45.08M81.17M
Shares Outstanding -------------93.50M96.53M100.19M112.64M

Cash Flows (Annual)

Figures in USD.

Metric Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Operating Cash Flow ------14.41M30.93M-380.00K18.33M-29.64M-1.47M--2.40M15.54M-11.90M2.86M
Investing Cash Flow -----3.69M8.26M17.82M17.77M-4.31M-3.73M--4.72M-12.68M-3.60M-8.52M
Financing Cash Flow -----5.89M-757.00K-54.54M-27.45M28.47M26.70M--15.37M-2.11M-3.95M-4.25M
Capital Expenditure -5.13M-4.02M-10.77M-15.13M-11.93M-10.45M-8.07M-5.03M-6.28M-4.31M-3.56M--4.72M-12.68M-3.60M-8.52M
Free Cash Flow ------24.85M22.86M-5.41M12.05M-33.95M-5.03M--7.12M2.86M-15.51M-5.66M
Net Change in Cash -------------22.49M746.00K-19.46M-9.91M
Share Buybacks ----------014.08M00--

Ratios (Annual)

Figures in %.

Metric Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Gross Margin % ------39.8%36.9%39.9%38.8%39.1%-37.2%34.4%32.0%32.1%
Operating Margin % -------1.2%-2.6%-0.9%0.1%3.3%-1.9%0.5%0.1%1.7%
Net Margin % -------6.4%-7.7%-5.9%-3.9%1.0%--1.2%-2.1%-3.5%-0.3%
ROE % -----36.0%-53.1%-42.7%-63.6%-49.1%-32.9%6.0%--10.1%-17.3%-34.5%-2.0%
ROCE % --11.0%-18.8%-25.2%-5.8%-6.5%-1.9%-8.1%-1.8%0.2%4.1%-3.1%0.8%0.2%2.8%

Shareholding Pattern

Insiders
4.09%
Institutions
69.15%
Public Float
72.10%

Top Institutional Holders

#Holder% HeldSharesValue
1 TCW Group, Inc. 13.00% 15.47M $5.85M
2 Blackrock Inc. 7.11% 8.46M $3.20M
3 Neuberger Berman Group, LLC 4.92% 5.86M $2.22M
4 Armistice Capital, LLC 4.74% 5.64M $2.13M
5 Weber Capital Management LLC /ADV 4.25% 5.06M $1.91M
6 Vanguard Capital Management LLC 3.72% 4.43M $1.68M
7 Geode Capital Management, LLC 2.00% 2.38M $900.91K
8 Mackenzie Financial Corporation 1.97% 2.35M $887.86K
9 Renaissance Technologies, LLC 1.93% 2.29M $866.91K
10 State Street Corporation 1.70% 2.02M $763.48K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ARAY

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks